Home›Stock Screener›Jubilant Pharmova›Intrinsic Value

Jubilant Pharmova Intrinsic Value

Jubilant Pharmova intrinsic value. Jubilant Pharmova (JUBLPHARMA) median intrinsic value is ₹886.75 from 9 valuation models (range ₹280–₹2333), vs current price ₹933.25 — -5.0% downside (Trading Near Calculated Value), margin of safety -5.2%. Browse Jubilant Pharmova annual reports for revenue, profit, balance sheet and cash flow data.

Market Price (CMP)
₹933.25
Primary Intrinsic Value
₹279.97
Market Cap
₹1493 Cr
-5.0% Downside
Median Value
₹886.75
Value Range
₹280 - ₹2333
Assessment
Trading Near Calculated Value
Safety Margin
-5.2%

JUBLPHARMA Valuation Methods Summary — DCF, Graham Number & P/E

Jubilant Pharmova intrinsic value across 9 models vs current price ₹933.25 — upside/downside and value range per method. Analyse JUBLPHARMA shareholder distribution to track promoter, FII and institutional holdings.

Method Type Intrinsic Value Range Upside/Downside Details
P/E Based Valuation earnings ₹279.97 ₹223.98 - ₹335.96 -70.0% EPS: ₹7.88, Sector P/E: 22x
Book Value Method asset ₹2333.12 ₹2099.81 - ₹2566.43 +150.0% Book Value/Share: ₹4435.00, P/B: 2.0x
Revenue Multiple Method revenue ₹1866.50 ₹1679.85 - ₹2053.15 +100.0% Revenue/Share: ₹5937.50, P/S: 2.0x
EBITDA Multiple Method earnings ₹1866.50 ₹1679.85 - ₹2053.15 +100.0% EBITDA: ₹980.00Cr, EV/EBITDA: 10x
Simple DCF (5Y) dcf ₹2333.12 ₹1866.50 - ₹2799.74 +150.0% CF Growth: 10.0%, Discount: 15%
PEG Ratio Method growth ₹279.97 ₹251.97 - ₹307.97 -70.0% EPS Growth: 8.0%, Fair P/E: 6.4x
Growth Adjusted P/E growth ₹279.97 ₹251.97 - ₹307.97 -70.0% Revenue Growth: 6.0%, Adj P/E: 15.5x
Graham Defensive Method conservative ₹886.75 ₹798.08 - ₹975.43 -5.0% EPS: ₹7.88, BVPS: ₹4435.00
Dividend Yield Method dividend ₹279.97 ₹251.97 - ₹307.97 -70.0% DPS: ₹5.00, Target Yield: 2.5%
Method Types: Earnings Asset DCF Growth Dividend Conservative

JUBLPHARMA Intrinsic Value vs Market Price — All Valuation Models

Jubilant Pharmova fair value range ₹280–₹2333 vs current market price ₹933.25 across 9 valuation models. For current market price and key ratios, visit JUBLPHARMA screener.

JUBLPHARMA Intrinsic Value Analysis — Undervalued or Overvalued?

Jubilant Pharmova median intrinsic value ₹886.75, current price ₹933.25 — Trading Near Calculated Value by 5.0%, margin of safety -5.2%.

What is the intrinsic value of JUBLPHARMA?

Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Jubilant Pharmova (JUBLPHARMA) is ₹886.75 (median value). With the current market price of ₹933.25, this represents a -5.0% variance from our estimated fair value.

The valuation range spans from ₹279.97 to ₹2333.12, indicating ₹279.97 - ₹2333.12.

Is JUBLPHARMA undervalued or overvalued?

Based on our multi-method analysis, Jubilant Pharmova (JUBLPHARMA) appears to be trading near calculated value by approximately 5.0%.

JUBLPHARMA Financial Health — Key Ratios vs Industry Benchmarks

Jubilant Pharmova financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Return on Equity 1.7% Industry Standard: 15%+ Below 10% Measures shareholder return efficiency
Operating Margin 10.0% Industry Standard: 20%+ Above 10% Indicates operational efficiency level
Asset Turnover Ratio 0.61x Industry Standard: 1.0x+ Above 0.5x Measures asset utilization efficiency

JUBLPHARMA Cash Flow Quality — Operating & Free Cash Flow

Jubilant Pharmova operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2026 ₹1,227 Cr ₹656 Cr Positive Free Cash Flow 8/10
March 2025 ₹1,072 Cr ₹1,072 Cr Positive Free Cash Flow 8/10
March 2024 ₹971 Cr ₹673 Cr Positive Free Cash Flow 8/10
March 2023 ₹661 Cr ₹424 Cr Positive Free Cash Flow 8/10
March 2022 ₹838 Cr ₹677 Cr Positive Free Cash Flow 8/10